Authors : Aseem Setia, Aseem Setia, Sankha Bhattacharya, Sankha Bhattacharya
DOI : 10.18231/j.ijpp.2021.016
Volume : 8
Issue : 2
Year : 2021
Page No : 97-99
Mucormycosis is a life-threatening fungal infection caused by a group of moulds known as mucormycetes.
It is a viral disease, increasingly progressive, rapidly triggers in diabetic, immunocompromised and trauma
patients. Diabetic patients seem to have the classic rhinocerebral variant. Rhinocerebral mucormycosis
begins as a nasal cavity, paranasal sinus, and orbital soft tissue infection. In immunocompetent patients,
direct injection also induces cutaneous form. Cutaneous mucormycosis occurs in soft tissue and may infect
underlying tissues. Mucormycosis is more frequent in people with major underlying disorders such as
diabetic acidosis or acute leukaemia and those taking corticosteroids or cytotoxic drugs. This disease
occurs in patients by inhaling fungus spores. Mucormycosis occurs in clinical manifestations. Disseminated
mucormycosis is a rare form of mucormycosis, affecting individuals with compromised immune systems.
The disease travels to other areas of the body, thereby being prevalent. Brain, core, spleen, eyes, and other
organs are among the organs that may be affected. Mucormycosis is a dangerous infection that requires
antifungal drugs such as amphotericin B, posaconazole, or isavuconazole. This compilation addresses
conceptual background on medicines used to treat mucormycosis, especially in India.
Keywords: Mucormycosis, Amphotericin B, Diabetic acidosis, COVID-19.